Literature DB >> 18058812

Quantitative, spatial resolution of the epigenetic field effect in prostate cancer.

Jyoti Mehrotra1, Shobha Varde, Haiying Wang, Hsiling Chiu, Janet Vargo, Karen Gray, Raymond B Nagle, Jaclyn R Neri, Abhijit Mazumder.   

Abstract

BACKGROUND: Although a field effect in which transformed cells extend beyond morphologically evident tumor has been proposed in cancer, little direct evidence exists as to its magnitude and spatial resolution. We tested this hypothesis using molecular techniques to detect epigenetic changes in the primary tumor and surrounding tissues.
METHODS: Ex vivo core biopsies, each spaced approximately 1 mm apart, were generated from 37 unique prostatectomy samples. The first core biopsy was confirmed to be histologically positive for cancer, and the subsequent biopsies were confirmed to be histologically negative. The methylation ratio of GSTP1, APC, RARbeta2, and RASSF1A were measured for all of the 159 cores.
RESULTS: No field effect, defined as absence of epigenetically transformed cells, for GSTP1 was observed whereas APC, RARbeta2, and RASSF1A showed a field effect up to 3 mm from the malignant core in three prostatectomy samples. Furthermore, for each case, different patterns of the field effect were observed. The field effect appeared most pronounced with RARbeta2. In 11 prostatectomy samples in which a second focus of cancer was identified, cells harboring RARbeta2 methylation extended a large distance away from the primary tumor in one sample. Bisulfite sequencing of RARbeta2 confirmed the presence of epigenetic aberrations.
CONCLUSIONS: This study quantifies previous observations of methylation in histologically negative samples and provides important assessment of field effects based on epigenetic events in cancer. These molecular approaches set the stage for consideration of such data in prospective trials for assessment of surgical margins and prediction of recurrence.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18058812     DOI: 10.1002/pros.20675

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  44 in total

1.  Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies.

Authors:  Bruce J Trock; Michelle J Brotzman; Leslie A Mangold; Joseph W Bigley; Jonathan I Epstein; David McLeod; Eric A Klein; J Stephen Jones; Songbai Wang; Theresa McAskill; Jyoti Mehrotra; Bhargavi Raghavan; Alan W Partin
Journal:  BJU Int       Date:  2011-11-11       Impact factor: 5.588

2.  ID4 is frequently downregulated and partially hypermethylated in prostate cancer.

Authors:  Anna Vinarskaja; Wolfgang Goering; Marc Ingenwerth; Wolfgang A Schulz
Journal:  World J Urol       Date:  2011-09-01       Impact factor: 4.226

3.  Rectal Optical Markers for In Vivo Risk Stratification of Premalignant Colorectal Lesions.

Authors:  Vadim Backman; Hemant K Roy; Andrew J Radosevich; Nikhil N Mutyal; Adam Eshein; The-Quyen Nguyen; Bradley Gould; Jeremy D Rogers; Michael J Goldberg; Laura K Bianchi; Eugene F Yen; Vani Konda; Douglas K Rex; Jacques Van Dam
Journal:  Clin Cancer Res       Date:  2015-05-19       Impact factor: 12.531

4.  MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer.

Authors:  Seong O Suh; Yi Chen; Mohd Saif Zaman; Hiroshi Hirata; Soichiro Yamamura; Varahram Shahryari; Jan Liu; Z Laura Tabatabai; Sanjay Kakar; Guoren Deng; Yuichiro Tanaka; Rajvir Dahiya
Journal:  Carcinogenesis       Date:  2011-02-23       Impact factor: 4.944

Review 5.  Clinically relevant genetic characterization of prostate tumors: how close are we to the goal?

Authors:  Yuri Tolkach; Florian Imkamp; Konstantin Godin; Hendrik Van Poppel
Journal:  Korean J Urol       Date:  2015-01-30

6.  Budget impact model: epigenetic assay can help avoid unnecessary repeated prostate biopsies and reduce healthcare spending.

Authors:  Wade Aubry; Robert Lieberthal; Arnold Willis; Grant Bagley; Simon M Willis; Andrew Layton
Journal:  Am Health Drug Benefits       Date:  2013-01

7.  Reduced Rate of Repeated Prostate Biopsies Observed in ConfirmMDx Clinical Utility Field Study.

Authors:  Kirk J Wojno; Frank J Costa; Robert J Cornell; Jeffrey D Small; Erik Pasin; Wim Van Criekinge; Joseph W Bigley; Leander Van Neste
Journal:  Am Health Drug Benefits       Date:  2014-05

8.  Using the epigenetic field defect to detect prostate cancer in biopsy negative patients.

Authors:  Matthew Truong; Bing Yang; Andrew Livermore; Jennifer Wagner; Puspha Weeratunga; Wei Huang; Rajiv Dhir; Joel Nelson; Daniel W Lin; David F Jarrard
Journal:  J Urol       Date:  2012-11-15       Impact factor: 7.450

9.  Methylation of the RARB gene increases prostate cancer risk in black Americans.

Authors:  Deliang Tang; Oleksandr N Kryvenko; Nicoleta Mitrache; Kieu C Do; Michelle Jankowski; Dhananjay A Chitale; Sheri Trudeau; Andrew Rundle; Steven A Belinsky; Benjamin A Rybicki
Journal:  J Urol       Date:  2013-01-30       Impact factor: 7.450

10.  Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays.

Authors:  Ken Kron; Vaijayanti Pethe; Laurent Briollais; Bekim Sadikovic; Hilmi Ozcelik; Alia Sunderji; Vasundara Venkateswaran; Jehonathan Pinthus; Neil Fleshner; Theodorus van der Kwast; Bharati Bapat
Journal:  PLoS One       Date:  2009-03-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.